Psychophysical health status of breast cancer survivors and effects of 12 weeks of aerobic training: Beyond the Abstract

In a recent harmonised meta-analysis of data from more than 1 million men and women, Ekelund and colleagues [1] reported the role of physical activity in the attenuation or elimination of the detrimental association between sitting time and mortality.
Read more ...

A clinical, histologic, and follow-up study of genital melanosis in men and women: Beyond the Abstract

Genital melanosis, a rare condition often characterized by large, asymmetrical and often mutli-focal pigmentation occurring on genital skin, is often mistaken for genital melanoma. As the literature on the topic is limited, management of these patients is often very difficult as little is known about the risk for progression to gential melanoma.  Although lesions biopsied from patients with genital melanosis show benign histologic features, providers may opt for further excisional procedures due to the concerning clinical appearance of these lesions and uncertainty about future melanoma risk. 
Read more ...

Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells: Beyond the Abstract

Ovarian cancer is the deadliest among women related cancers due to problems in early detection and treatment. It is seen that initially, the cancer responds well to therapy; however, in majority of advanced cases, the ovarian tumors relapse with a resistant disease profile. 
Read more ...

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan: Beyond the Abstract

High-dose chemotherapy with single-agent melphalan followed by an autologous stem-cell transplant (ASCT) results in significant benefit as a front-line consolidation therapy for chemosensitive myeloma. In contrast, the efficacy of high-dose melphalan for relapsed or refractory myeloma is much lower, with only 5–10% of patients achieving complete remission (CR) and median progression-free survival (PFS) of about 12 months after ASCT. 
Read more ...

Use of prostatic specific antigen in primary care (PSA): Beyond the Abstract

The conclusions and the use that have surrounded the prostate-specific antigen (PSA) since its incorporation into the usual clinical practice during the 1990s have varied over the years. Like any screening tool, it should serve to detect the largest number of cases (by excess), minimizing the number of false negatives, in addition to achieving an increase in the survival of an oncological disease such as prostate cancer, considered the more prevalent solid neoplasia in Europe (1).
Read more ...

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report: Beyond the Abstract

Epidermal growth factor receptor (EGFR) inhibitors are a class of biological agents which act on the ErbB family of tyrosine kinases. They are widely used for treating cancer.  The toxicity profile of these oral drugs is different from that of chemotherapy: cutaneous toxicity is the second most commonly reported adverse event (AE) after the gastrointestinal one (diarrhea, nausea). 
Read more ...

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience: Beyond the Abstract

Pancreatic ductal adenocarcinoma (PDAC) is now the 3rd leading cause of cancer-related mortality in the United States. The poor prognosis of PDAC patients is highlighted by the fact that the majority present with metastatic disease. However, even those with localized cancers who undergo surgical resection are likely to recur. While the outcomes of surgery are marginally improved with the addition of adjuvant chemotherapy and/or radiation therapy, many patients may never receive these therapies following surgery because of either surgical complications, early disease progression or poor patient performance status.
Read more ...
@OncToday